Known targets — ChEMBL curated mechanism
KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2
The experimentally established mechanism targets of Guanidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Guanidine SCHEMBL27608132 | 1.00 | CA1 (0.50) | CA1CA2 | |
| Guanidine SCHEMBL28942 | 1.00 | — | — | |
| Guanidine SCHEMBL28279993 | 1.00 | CA1 (0.50) | CA1CA2 | |
| Guanidine SCHEMBL2929472 | 1.00 | CA1 (0.50) | CA1CA2 | |
| Guanidine SCHEMBL6364290 | 0.96 | — | — | |
| Guanidine SCHEMBL6471890 | 0.96 | — | — | |
| Guanidine SCHEMBL21001927 | 0.96 | — | — | |
| Guanidine SCHEMBL392029 | 0.96 | CA1 (0.46) | CA1CA2 | |
| Guanidine SCHEMBL3669881 | 0.96 | — | — | |
| Guanidine SCHEMBL8647467 | 0.93 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114854903-A | Method for detecting the presence of severe acute respiratory syndrome coronavirus 2 in a biological sample | 泰利福医疗公司 | 2022-08-05 | — | — | CN | claimed |
| CN-113832257-A | Detection system for severe acute respiratory syndrome coronavirus 2 | 泰利福医疗公司 | 2021-12-24 | — | — | CN | claimed |
| EP-3904537-A2 | METHOD OF IDENTIFYING SEVERE ACUTE RESPIRATORY SYNDROME CORONA VIRUS 2 (SARS-COV-2) RIBONUCLEIC ACID (RNA) | Teleflex Medical Incorporated (US) | 2021-11-03 | — | — | EP | claimed |
| EP-3904538-A2 | SYSTEM FOR IDENTIFYING SEVERE ACUTE RESPIRATORY SYNDROME CORONA VIRUS 2 (SARS-COV-2) RIBONUCLEIC ACID (RNA) | Teleflex Medical Incorporated (US) | 2021-11-03 | — | — | EP | claimed |
| US-20210130886-A1 | METHOD OF IDENTIFYING SEVERE ACUTE RESPIRATORY SYNDROME CORONA VIRUS 2 (SARS-COV-2) RIBONUCLEIC ACID (RNA) | TELEFLEX MEDICAL INCORPORATED | 2021-05-06 | — | — | US | claimed |
| US-20210129144-A1 | SYSTEM FOR IDENTIFYING SEVERE ACUTE RESPIRATORY SYNDROME CORONA VIRUS 2 (SARS-COV-2) RIBONUCLEIC ACID (RNA) | TELEFLEX MEDICAL INCORPORATED | 2021-05-06 | — | — | US | claimed |
| WO-2021046343-A1 | LYSING SOLUTION FOR REAL-TIME DETERMINING THE IDENTIFICATION AND ANTIBIOTIC RESISTANCE OF PATHOGENIC MICROORGANISMS | TELEFLEX MEDICAL INCORPORATED (US) | 2021-03-11 | — | — | WO | claimed |
| WO-2021046504-A1 | INFECTION DETECTION SYSTEMS AND METHODS INCLUDING A SAMPLE PROCESSOR HAVING INTEGRATED SAMPLE FILTER AND METER | TELEFLEX MEDICAL INCORPORATED (US) | 2021-03-11 | — | — | WO | claimed |
| WO-2021046506-A1 | INFECTION DETECTION SYSTEMS AND METHODS INCLUDING INTERMEDIATE FILTERING AND METERING | TELEFLEX MEDICAL INCORPORATED (US) | 2021-03-11 | — | — | WO | claimed |
| EP-3904537-A2 | METHOD OF IDENTIFYING SEVERE ACUTE RESPIRATORY SYNDROME CORONA VIRUS 2 (SARS-COV-2) RIBONUCLEIC ACID (RNA) | Teleflex Medical Incorporated (US) | 2021-11-03 | — | — | EP | disclosed |
| EP-3904538-A2 | SYSTEM FOR IDENTIFYING SEVERE ACUTE RESPIRATORY SYNDROME CORONA VIRUS 2 (SARS-COV-2) RIBONUCLEIC ACID (RNA) | Teleflex Medical Incorporated (US) | 2021-11-03 | — | — | EP | disclosed |
| US-20210130886-A1 | METHOD OF IDENTIFYING SEVERE ACUTE RESPIRATORY SYNDROME CORONA VIRUS 2 (SARS-COV-2) RIBONUCLEIC ACID (RNA) | TELEFLEX MEDICAL INCORPORATED | 2021-05-06 | — | — | US | disclosed |
| US-20210129144-A1 | SYSTEM FOR IDENTIFYING SEVERE ACUTE RESPIRATORY SYNDROME CORONA VIRUS 2 (SARS-COV-2) RIBONUCLEIC ACID (RNA) | TELEFLEX MEDICAL INCORPORATED | 2021-05-06 | — | — | US | disclosed |
| WO-2021046343-A1 | LYSING SOLUTION FOR REAL-TIME DETERMINING THE IDENTIFICATION AND ANTIBIOTIC RESISTANCE OF PATHOGENIC MICROORGANISMS | TELEFLEX MEDICAL INCORPORATED (US) | 2021-03-11 | — | — | WO | disclosed |
| WO-2021046506-A1 | INFECTION DETECTION SYSTEMS AND METHODS INCLUDING INTERMEDIATE FILTERING AND METERING | TELEFLEX MEDICAL INCORPORATED (US) | 2021-03-11 | — | — | WO | disclosed |
| WO-2021046504-A1 | INFECTION DETECTION SYSTEMS AND METHODS INCLUDING A SAMPLE PROCESSOR HAVING INTEGRATED SAMPLE FILTER AND METER | TELEFLEX MEDICAL INCORPORATED (US) | 2021-03-11 | — | — | WO | disclosed |
| WO-2021046343-A1 | LYSING SOLUTION FOR REAL-TIME DETERMINING THE IDENTIFICATION AND ANTIBIOTIC RESISTANCE OF PATHOGENIC MICROORGANISMS | TELEFLEX MEDICAL INCORPORATED (US) | 2021-03-11 | — | — | WO | disclosed |